Table 2.
DNA methylation changes in the VMP1/MIR21 locus in CD4+ T cells from RR-MS and SP-MS patients and HC.
| Probe IDa | Genea | Featurea | ALLb |
RR vs HCb |
RR vs SPb |
SP vs HCb |
|||
|---|---|---|---|---|---|---|---|---|---|
| p-val (M) | Eff (Δβ) | p-val (M) | Eff (Δβ) | p-val (M) | Eff (Δβ) | p-val (M) | |||
| cg20458044 | VMP1 | Intron | 1E-01 | 0.04 | 2E-01 | 0.07 | 4E-02 | –0.03 | 3E-01 |
| cg16936953 | VMP1 | Exon | 2E-03 | 0.06 | 6E-02 | 0.10 | 5E-04 | –0.04 | 4E-02 |
| cg12054453 | VMP1 | Exon | 4E-03 | 0.03 | 9E-02 | 0.04 | 1E-03 | –0.02 | 5E-02 |
| cg01409343 | VMP1 | Exon | 1E-02 | 0.06 | 7E-02 | 0.10 | 3E-03 | –0.04 | 2E-01 |
| cg18942579 | VMP1 | Intron | 4E-04 | 0.08 | 1E-02 | 0.12 | 1E-04 | –0.05 | 6E-02 |
| cg02782634 | VMP1 | Intron | 4E-03 | 0.10 | 5E-02 | 0.17 | 1E-03 | –0.08 | 8E-02 |
| cg14032089 | MIR21 | TSS1500 | 3E-02 | 0.09 | 7E-02 | 0.14 | 1E-02 | –0.05 | 3E-01 |
| cg27023597 | MIR21 | TSS1500 | 2E-04 | 0.12 | 2E-03 | 0.16 | 6E-05 | –0.04 | 1E-01 |
| cg04276626 | MIR21 | TSS200 | 7E-02 | 0.08 | 1E-01 | 0.12 | 3E-02 | –0.04 | 4E-01 |
| cg02515217 | MIR21 | TSS200 | 4E-03 | 0.12 | 2E-02 | 0.17 | 2E-03 | –0.05 | 3E-01 |
| cg15759721 | MIR21 | Body | 9E-03 | 0.11 | 4E-02 | 0.14 | 3E-03 | –0.04 | 2E-01 |
| cg07181702 | MIR21 | Body | 2E-03 | 0.14 | 7E-03 | 0.18 | 9E-04 | –0.04 | 3E-01 |
| cg22663389 | – | IGR | 6E-01 | –0.00 | 3E-01 | –0.00 | 6E-01 | –0.00 | 7E-01 |
MS: multiple sclerosis; RR: relapsing-remitting multiple sclerosis; SP: secondary-progressive multiple sclerosis; HC: healthy controls.
a
CpG probe ID, annotated gene names and genomic features from 450K arrays.
b
M-values (indicated by M) were used to compare RR-MS patients (RR; n = 12), SP-MS patients (SP; n = 8), and healthy controls (HC; n = 12), and p-values (p-val) were derived using a linear modeling that included MS status, age, and sex as covariates. The effect size (Eff) represents a difference in β-values (Δβ) between the groups for each probe. p-val <0.05 are indicated in bold.